DCLL-9718S
- Generic Name
- DCLL-9718S
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
DCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1). DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03298516
- Locations
- 🇺🇸
Columbia University Medical Center; Research Pharmacy, Irving Pavillion, Ip 7-749, New York, New York, United States
🇨🇦Jewish General Hospital / McGill University, Montreal, Quebec, Canada
🇨🇦University of Alberta Hospital, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.